Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.71 |
| ▸ | ERBB2 | P04626 | 12/20 | 0.71 |
| ▸ | FECH | P22830 | 1/20 | 0.71 |
| ▸ | CDK8 | P49336 | 1/20 | 0.71 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.71 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.71 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.71 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.45 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.45 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4617012 | 1.00 | EGFR (0.71) | EGFRERBB2FECHCDK8MAP2K5 | |
| SCHEMBL6175088 | 0.92 | EGFR (0.74) | EGFRERBB2FECHCDK8MAP2K5 | |
| SCHEMBL6174127 | 0.92 | EGFR (0.74) | EGFRERBB2FECHCDK8MAP2K5 | |
| SCHEMBL6175084 | 0.92 | EGFR (0.74) | EGFRERBB2FECHCDK8MAP2K5 | |
| SCHEMBL6174132 | 0.92 | EGFR (0.74) | EGFRERBB2FECHCDK8MAP2K5 | |
| SCHEMBL5982303 | 0.92 | ERBB2 (0.83) | EGFRERBB2FECHCDK8MAP2K5 | |
| SCHEMBL6170353 | 0.92 | ERBB2 (0.83) | EGFRERBB2FECHCDK8MAP2K5 | |
| SCHEMBL6175901 | 0.92 | ERBB2 (0.83) | EGFRERBB2FECHCDK8MAP2K5 | |
| SCHEMBL4798789 | 0.92 | EGFR (0.73) | EGFRERBB2FECHCDK8MAP2K5 | |
| SCHEMBL6174849 | 0.92 | EGFR (0.73) | EGFRERBB2FECHCDK8MAP2K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194596-A1 | Therapeutic Combination Including a Selective Erbb2 Inhibitor | FRIZER INC. | 2008-08-14 | — | — | US | claimed |
| EP-1896030-A1 | COMBINATIONS OF ERBB2 INHIBITORS WITH OTHER THERAPEUTIC AGENTS IN THE TREATMENT OF CANCER | Pfizer Products Incorporated (US) | 2008-03-12 | — | — | EP | claimed |
| EP-1448551-B1 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | OSI PHARM INC (US) | 2007-10-31 | — | — | EP | claimed |
| WO-2006129163-A1 | COMBINATIONS OF ERBB2 INHIBITORS WITH OTHER THERAPEUTIC AGENTS IN THE TREATMENT OF CANCER | PFIZER PRODUCTS INC. (US) | 2006-12-07 | — | — | WO | claimed |
| EP-1682176-A1 | SELECTIVE ERBB2 INHIBITOR/ANTI-ERBB ANTIBODY COMBINATIONS IN THE TREATMENT OF CANCER | Pfizer Products Inc. (US) | 2006-07-26 | — | — | EP | claimed |
| EP-1658080-A1 | DOSING SCHEDULE FOR A ERBB2 ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | claimed |
| EP-1615910-A1 | PROCESSES FOR THE PREPARATION OF N-((((PYRIDINYLOXY)-PHENYLAMINO)QUINAZOLINYL)-ALLYL)ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS WELL AS INTERMEDIATES OF SUCH PROCESSES AND PROCESSES FOR THE PREPARATION OF SUCH INTERMEDIATES | Pfizer Products Inc. (US) | 2006-01-18 | — | — | EP | claimed |
| US-20050159435-A1 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | PFIZER INC | 2005-07-21 | — | — | US | claimed |
| US-20050119288-A1 | Dosing schedule for a novel anticancer agent | PFIZER INC | 2005-06-02 | — | — | US | claimed |
| WO-2005044302-A1 | SELECTIVE ERBB2 INHIBITOR/ANTI-ERBB ANTIBODY COMBINATIONS IN THE TREATMENT OF CANCER | PFIZER PRODUCTS INC. (US) | 2005-05-19 | — | — | WO | claimed |
| WO-2004089934-A1 | PROCESSES FOR THE PREPARATION OF N-((((PYRIDINYLOXY) -PHENYLAMINO) QUINAZOLINYL)- ALLYL) ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS WELL AS INTERMEDIATES OF SUCH PROCESSES AND PROCESSES FOR THE PREPARATION OF SUCH INTERMEDIATES | PFIZER PRODUCTS INC. (US) | 2004-10-21 | — | — | WO | claimed |
| EP-1465632-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | Pfizer Products Inc. (US) | 2004-10-13 | — | — | EP | claimed |
| EP-1448551-A1 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | Pfizer Products Inc. (US) | 2004-08-25 | — | — | EP | claimed |
| US-20030171386-A1 | Small molecules for the treatment of abnormal cell growth | PFIZER INC. | 2003-09-11 | — | — | US | claimed |
| US-20030144506-A1 | Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth | PFIZER INC. | 2003-07-31 | — | — | US | claimed |
| WO-2003049740-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2003-06-19 | — | — | WO | claimed |
| WO-2003045939-A1 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2003-06-05 | — | — | WO | claimed |
| EP-1292591-A2 | SUBSTITUTED BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | Pfizer Products Inc. (US) | 2003-03-19 | — | — | EP | claimed |
| US-20020169165-A1 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | PFIZER PRODUCTS INC. | 2002-11-14 | — | — | US | claimed |
| WO-2001098277-A2 | SUBSTITUTED BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2001-12-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169165-A1 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | CCNA1, CCNT1, CCNB1 | EGFR 119/4885ERBB2 755/4885FECH 3297/4885 |
| US-20050119288-A1 | Dosing schedule for a novel anticancer agent | ERBB2, ERBB3, EGFR | EGFR 3/4885ERBB2 1/4885FECH 4515/4885 |
| US-20080194596-A1 | Therapeutic Combination Including a Selective Erbb2 Inhibitor | ERBB2, ERBB3, EGFR | EGFR 3/4885ERBB2 1/4885FECH 3926/4885 |
| US-20050159435-A1 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | CCNA1, CCNT1, CCNB1 | EGFR 164/4885ERBB2 883/4885FECH 2655/4885 |
| US-20030171386-A1 | Small molecules for the treatment of abnormal cell growth | ERBB2, EGFR, ERBB3 | EGFR 2/4885ERBB2 1/4885FECH 4706/4885 |
| US-20030144506-A1 | Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth | CCNA1, CCNE1, CCNT1 | EGFR 148/4885ERBB2 1149/4885FECH 3419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.